Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. [electronic resource]
Producer: 20120312Description: 1446-55 p. digitalISSN:- 1879-114X
- Adolescent
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- China
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Disease Progression
- Disease-Free Survival
- Endostatins -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Markov Chains
- Middle Aged
- Models, Economic
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.